Half-year Report

LONDON STOCK EXCHANGE ANNOUNCEMENT

Pacific Assets Trust plc

(the “Company” or the “Trust”)

Unaudited Half Year Results For The Six Months Ended 31 July 2021

This announcement is not the Company’s Half Year Report. It is an abridged version of the Company’s full Half Year Report for the six months ended 31 July 2021. The full Half Year Report, together with a copy of this announcement, will shortly be available on the Company’s website at www.pacific-assets.co.uk where up to date information on the Company, including daily NAV, share prices and fact sheets, can also be found.

The Company's Half Year Report for the six months ended 31 July 2021 has been submitted to the UK Listing Authority, and will shortly be available for inspection on the National Storage Mechanism (NSM): https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information please contact: Katherine Manson, Frostrow Capital LLP, 020 3709 8734.

Financial Highlights

Key Statistics

	As at	As at
	31 July	31 January
	2021	2021	% change
Share price	336.0p	333.0p	0.9%
Net asset value per share	359.6p	344.1p	4.5%
Discount of share price to net asset value per share	6.5%	3.2%
Market capitalisation	£406.4m	£402.8m	0.9%
Shareholders’ funds	£435.0m	£416.2m	4.5%

	Six months to	One year to
	31 July	31 January
	2021	2021
Share price (total return)*^	1.7%	25.8%
Net asset value per share (total return)*^	5.6%	22.3%
CPI + 6%1	5.1%	6.8%
MSCI All Country Asia ex Japan Index (total return, sterling adjusted)*	(6.6%)	30.7%
Average discount of share price to net asset value per share^	7.0%	9.1%
Ongoing charges^	1.1%	1.1%

*Source: Morningstar.

^{^}Alternative Performance Measure (see Glossary).

¹UK Consumer Price Index + 6% – the Company’s Performance Objective (see Glossary).

	Year ended	Year ended
	31 January	31 January
Dividends	2021	2020
Dividend per share	2.4p	3.0p

Peer Group Performance

Performance Assessment

Pacific Assets Trust plc exists in a competitive environment and aims to be a leader in its peer group, defined as being consistently within the top third of that group measured by net asset value per share total return. The Company is committed to building a long-term investment record and will assess itself by reference to its peers on a rolling three to five-year basis. An analysis of this performance can be found in the Chairman’s Statement and the Portfolio Manager’s Review.

Peer Group Net Asset Value per Share Total Return^

	1 Year		3 years		5 years
	£	Rank	£	Rank	£	Rank
Pacific Horizon	162.1	1	222.3	1	349.3	1
Schroder Asian Total Return	126.0	4	144.7	2	207.1	2
Schroder Asia Pacific	123.5	6	133.6	3	192.9	3
Invesco Asia	125.5	5	133.5	4	179.3	5
Asia Dragon	117.8	7	133.0	5	172.9	6
Pacific Assets Trust	126.6	3	131.4	6	166.2	7
JP Morgan Asian	116.3	8	130.9	7	190.2	4
Fidelity Asian Values	140.2	2	126.8	8	152.6	9
iShares MSCI Asia ex Jpn ETF	111.3	9	119.6	9	159.9	8
Peer Group Average	127.7		141.8		196.7
CPI + 6%1	108.8		125.9		149.1
MSCI AC Asia ex Japan	112.4		122.3		165.8

Source: Morningstar. Figures show the value as at 31 July 2021 of £100 invested at the start of the period.

^ Alternative Performance Measure (see Glossary).

1 The Company’s Performance Objective (see Glossary).

Chairman’s Statement

The interim period for the Company closed on 31st July. At that time the news was dominated by the delayed Tokyo Olympics being held behind closed doors, and the financial news by a series of regulations and prohibitions affecting Chinese companies. These are just a reminder of how unpredictable things have become, neither situation could easily have been anticipated a year or two ago.

Over the six months to 31st July 2021, the net asset value of the Company’s shares rose by 5.6%^{^} on a total return basis. Such a trend was in line with most global stock markets which had risen comfortably notwithstanding the seemingly endless economic disruption by the pandemic. The Company’s annualised net asset value total return per share has been 9.5% over three years and 10.7% over the last five years. Over these longer periods, it is comfortably ahead of our Performance Objective, UK CPI plus 6%, which has increased 8.0% and 8.3% on an annual basis over these periods. We also use a peer group of Asian investment trusts as a comparator, and while still in the lower half of the range of returns over three and five years, your Company has shown relative improvement over the last year.  The latest figures are shown above.

Our relative returns over recent years have been affected by the Trust’s reluctance to engage fully in the powerful wave of Chinese investment themes. This approach owed much to the lack of transparency within Chinese companies, and the belief that the Chinese Communist Party (“CCP”) could still overpower company management for ideological or political reasons. The CCP being synonymous with the Government meant that we could never have full confidence that our shareholders’ assets could be secure against a rapid change in political sentiment. Where the larger Chinese companies are concerned, there seems to be an unhealthy mixture with geopolitics, so that foreign listings (notably New York) and special purpose vehicles used to access some (the Variable Interest Entity structure) have been vulnerable.

All this is now widely understood and possibly discounted as prominent Chinese shares have fallen substantially, justifying our Portfolio Manager's long held decision to be underweight Chinese securities. However, the Trust has ventured modestly into China, more so recently. It is invested in less high profile companies, particularly in the fields of medicine and diagnostics. We are encouraged that the euphoria of recent years has been punctured, and that more opportunities will be provided in China. It is easy to be overwhelmed by the commentary on the politics and miss the extraordinary creativity and economic dynamism that is flourishing throughout the country.

Our Portfolio Manager is discriminating in seeking out quality franchises. Some of these are to be found in China, and many elsewhere, notably in India. One of the most positive contributors to return in the period has been Marico, an Indian stock that has been held by the Trust for more than 10 years. At the same time, in a sometimes volatile market, it is encouraging how many new names are appearing in the portfolio, that meet the exacting standards we apply.

James Williams

Chairman

25 October 2021

^ Alternative Performance Measure (see Glossary).

Portfolio Manager’s Review

Performance overview

The Company’s net asset value per share total return over the half year was 5.6%. This compares to an increase in the Company’s Performance Objective¹ of 5.1% and a 6.6% decrease in the MSCI AC Asia ex Japan Index (measured on a total return, sterling adjusted basis). These numbers point at a feature of the year so far, a significant divergence in performance between countries in the Asia Pacific region. In China, strengthening political headwinds had a chilling impact on equities whereas, in stark contrast, equities in India proved to be very popular. Six of the portfolio’s largest detractors were companies operating in China, while seven of the largest positive contributors were from India. We have found that quality and sustainability transcend borders and focusing on geography can be distracting. The Trust invests in companies and not countries, but we do consider headwinds and tailwinds and the sheer size of this performance differential bears examination.

What detracted from our return?

During the interim period many equities in China became less popular as political headwinds strengthened against certain areas of the economy. Companies falling foul of greater government scrutiny appeared to possess three main characteristics: prominent stewards deemed capable of challenging higher powers; franchises considered to be misaligned with social development; and foreign investors facilitated by American Depositary Receipt (“ADR”) listings and/or corporate structures containing variable interest entities. American listed education companies were sanctioned heavily. Here, it was decreed that profit from the provision of private tuition was incompatible with social development. By prohibiting these companies from making profit the government effectively confiscated the assets. Shareholders lost more than 90% within a few weeks. Fortunately, our focus on quality companies spared shareholders from the worst of these tribulations, but political anxieties, particularly in China and Hong Kong, did have a small negative impact on performance.

The biggest detractor from performance was Vitasoy, one of the largest holdings in the portfolio. Vitasoy is a plant-based beverage manufacturer that is listed in Hong Kong and expanding in China. Following an unpredictable debacle, external to company purview, Vitasoy featured negatively in the national and international press. This led to a social media outcry, a boycott of their products by Chinese consumers and ultimately a profit warning. A recent call with management confirmed their competence and that demand for Vitasoy’s products was rebounding. We are encouraged that the worst of this episode is in the past and the Trust remains invested in this high-quality franchise.

Five other companies operating in China were also weak, but the cumulative detraction was less than from Vitasoy alone. These companies were Unicharm Corporation, Pigeon Corporation, Vinda International, Hualan Biological and AK Medical. Rising input prices had a marginal short-term impact on manufacturers, but there were no discernible political headwinds facing any of these companies, save for the possibility of reduced product pricing at AK Medical. This written, we are not complacent and we continue to evaluate any challenges to capital preservation with a sharpened focus on political risk.

Outside China, equities in South East Asia were mostly lacklustre. The portfolio suffered small performance detractions from Philippine Seven, a convenience store operator headquartered in Manila; Humanica, a human resources and accounting specialist in Thailand; and Bank OCBC Nisp in Indonesia. These companies are particularly sensitive to local lockdown and economic challenges and their recent weakness is understandable. The Trust remains invested in these companies as their deep financial resilience, excellent stewardship and strong franchises mean they are well placed to contribute to future returns as economies recover.

¹ Consumer Price Index (“CPI”) + 6%. CPI data is quoted on a one month lag. See Glossary for further information.

What contributed to our return?

Indian companies contributed positively to performance regardless of their sector. The strongest contributor was Dr Lal Pathlabs which conducts medical tests in radiology, pathology and cardiology. The title of their recently released annual report, “Enabling Healthier Lives”, provides a good explanation for this strength as well as highlighting excellent sustainability credentials. Dr Lal’s supplemented their core franchise expansion with Covid testing facilities and the value of the equity rose by nearly 60% in local terms. Despite a pandemic induced boost, the company only tests 20 million patients a year and we are comfortable that there is significant growth potential for this franchise as high-quality operators continue to take market share in a relatively unorganised market.

The second largest contributor was Tube Investments. Tube is expertly stewarded by Mr Vellayan Subbiah, a descendant of the Murugappa family who founded a conglomerate spanning 28 businesses across India and beyond over 120 years ago. The company is currently one of India’s leading manufacturers of metal formed products for automotive, railway, construction and agriculture as well as a leading manufacturer of bicycles. Since taking the reins in 2017, Velleyan has improved the balance sheet, returns on capital and free cash flow generation. This has set the scene for Tube’s long-term ambition to evolve into a high-quality industrial conglomerate capable of reinvesting free cash flow from existing businesses into new growth engines. This year, we witnessed their first major move with the acquisition of CG Power, a high-quality motor franchise that had been severely mismanaged by previous owners. We have spent a lot of time trying to understand how successful industrial conglomerates have evolved globally and believe Tube has many of the right credentials for long-term success.

The third strongest contributor was Marico. Marico is the dominant provider of hair conditioning and healthy edible oils² in India and is also present in Bangladesh, Vietnam and parts of the Middle East and North Africa. Aided by the pandemic, the company enjoyed a strong year on the back of a consumer inclination towards better hygiene and healthier eating. After a number of years of investment, we are now seeing their healthy foods business become a material contributor to growth and profitability.

Only slightly less substantial, but no less important, other notable contributors to performance were Cyient, Sundaram Finance and Elgi Equipment, all from India. Each of these companies enjoyed a rebound in operations and investor interest following extreme Covid related weakness in 2020. Lastly, a relatively new investment in Tata Consumer Products performed well as the CEO, Sunil D’Souza, showed progress removing ineffciencies from this newly created consumer franchise.

Of course, India was not the only focus and three of the top ten contributors were from China, South Korea and Hong Kong, namely Silergy, Naver and Techtronic.

Silergy is listed in Taiwan, but operates in China, and designs analog semiconductors, mostly for power management and effciency. Global demand for integrated circuits has continued to be strong with shortages in supply documented across countries and industries. Additionally, Silergy also benefits from a localisation trend as China seeks semiconductor manufacturing independence from foreign suppliers.

Naver is listed in South Korea and started in 2000 as a search engine dedicated to Korean users. Since then, the group has prudently parlayed prodigious cash-flows from search advertising revenues into a powerful internet ecosystem offering financial services, media, commerce and cloud capabilities. The steward here is Seong-sook Han and we have great admiration for the vibrant, innovative and differentiated culture she has nurtured. Naver, like all companies, is imperfect and we have been engaging, with some success, on certain unwelcome employment practices. During the period Naver benefitted from the increased need for virtual connectivity making it easier to launch and develop new services within their expanding eco-system.

The last significant contributor to performance was Techtronic, which is listed in Hong Kong. Techtronic is one of only three major competitors in the now consolidated power tool manufacturing industry. During the period Techtronic continued to benefit from buoyant demand from personal and commercial construction activities. They also strengthened their industry position as the marketplace continues to transition to cordless power tool technology, which is dominated by Techtronic.

² Marico’s domestic market share of coconut oil hair conditioning and super premium refined edible oils is 61% and 81%. Marico Investor Presentation, May 2021 https://m.marico.com/investorspdf/Investor_Presentation_May_2021.pdf

Transactions

The Trust purchased three new companies in China: Glodon, which provides digital design and imaging services to the construction industry; Estun Automation, a manufacturer of industrial automation; and Amoy Diagnostics, which specialises in the early-stage detection of cancer.

Having sold the Trust’s entire holding in Nippon Paint in November 2020, for reasons of valuation only, with the share price weakening since that time and with our confidence in the quality of its people, franchise and financials undiminished, we reinitiated a holding in the period under review.

In India, we purchased four new franchises with strong growth opportunities: CG Power & Industrial, which has a long history and strong franchise manufacturing equipment for power generation, transmission and distribution; Cholamandalam Financial Holdings (a subsidiary of the Murugappa Group), which provides insurance and investments; Indiamart Intermesh, which digitally connects buyers and sellers with over 72,000 mostly industrial components and goods; and lastly, Biocon, which is a contract researcher and manufacturer of pharmaceuticals.

The Trust sold out of four investments in the period. Two of these were banks: OCBC in Singapore and Bank of Central Asia in Indonesia. The environment for banks is challenging with new competitors and a diminished outlook for profitable loan growth. We also sold Metropolis Healthcare and Indigo Paints. Both of these were small holdings which we did not want to increase for reasons of valuation.

Outlook

The Trust invests in companies and not in countries. When constructing the portfolio we start with a blank sheet of paper and invest in companies with strong sustainability positioning and high-quality franchises, people and financials. When evaluating companies, we also consider political and economic headwinds and tailwinds. These exacerbate weaknesses and magnify qualities. During the interim period under review, political headwinds in China strengthened. This exposed the legal or social frailties of many well-known but lower quality companies. In the future, these political headwinds may wane but the Trust will not compromise on quality and will continue to invest in the highest quality stewards, franchises and financials to preserve and grow shareholders’ capital.

Stewart Investors

25 October 2021

Contribution by investment for the six months ended 31 July 2021

Top 10 contributors to and detractors from absolute performance (%)

Top 10 contributors to absolute performance for the 6 months ended 31 July 2021

	Contribution to
Company	Returns %
Dr Lal Pathlabs	1.23
Tube Investments	1.21
Marico	0.79
Silergy	0.64
Cyient	0.50
Tata Consumer Products	0.49
Sundaram Finance	0.48
NAVER	0.47
Techtronic Industries	0.47
Elgi Equipments	0.45

Top 10 detractors from absolute performance for the 6 months ended 31 July 2021

	Contribution to
Company	Returns %
Vitasoy International Holdings	-1.63
Unicharm Corporation	-0.42
Pigeon Corporation	-0.37
Vinda International Holdings	-0.30
Hualan Biological	-0.25
Philippine Seven	-0.24
Humanica	-0.24
Bank OCBC	-0.22
AK Medical Holdings	-0.16
Kotak Mahindra Bank	-0.14

Source: Stewart Investors.

Portfolio Valuation

as at 31 July 2021

			Val’n	% Total
Company	Sector	Country	£000	Assets
Hoya Corp	Health Care	Japan	18,374	4.2%
Tube Investments of India	Consumer Discretionary	India	17,847	4.1%
Mahindra & Mahindra	Consumer Discretionary	India	15,597	3.6%
Marico	Consumer Staples	India	15,257	3.5%
Unicharm	Consumer Staples	Japan	13,322	3.1%
Techtronic Industries	Industrials	Hong Kong	12,901	3.0%
Vitasoy International Holdings	Consumer Staples	Hong Kong	12,683	2.9%
Voltronic Power Technology	Industrials	Taiwan	12,080	2.8%
Housing Development Finance Corporation	Financials	India	11,771	2.7%
NAVER	Communication Services	South Korea	11,696	2.7%
Top 10 Investments			141,528	32.6%
Dr Lal Pathlabs	Health Care	India	10,910	2.5%
Koh Young Technology	Information Technology	South Korea	9,728	2.2%
Taiwan Semiconductor Manufacturing	Information Technology	Taiwan	9,144	2.1%
Tata Consultancy Services	Information Technology	India	9,098	2.1%
Tata Consumer Products	Consumer Staples	India	8,994	2.1%
Kotak Mahindra Bank	Financials	India	8,844	2.0%
Delta Electronics	Information Technology	Taiwan	8,539	2.0%
Advantech	Information Technology	Taiwan	8,420	1.9%
Vinda International	Consumer Staples	China	8,130	1.9%
Silergy	Information Technology	China	7,823	1.8%
Top 20 Investments			231,158	53.2%
Info Edge	Communication Services	India	7,260	1.7%
Aavas Financiers	Financials	India	7,198	1.7%
Chroma Ate	Information Technology	Taiwan	7,178	1.7%
Dabur India	Consumer Staples	India	7,140	1.6%
Elgi Equipments	Industrials	India	7,027	1.6%
Dr. Reddy’s Laboratories	Health Care	India	6,793	1.6%
PT Uni-Charm Indonesia	Consumer Staples	Indonesia	6,668	1.5%
CG Power & Industrial Solutions	Industrials	India	6,590	1.5%
Vitrox	Information Technology	Malaysia	6,386	1.5%
Tech Mahindra	Information Technology	India	6,213	1.4%
Top 30 Investments			299,611	69.0%
Godrej Consumer Products	Consumer Staples	India	6,137	1.4%
Sundaram Finance	Financials	India	6,056	1.4%
Tata Communications	Communication Services	India	5,705	1.3%
Philippine Seven	Consumer Staples	Philippines	5,646	1.3%
Infosys	Information Technology	India	5,426	1.2%
Bank OCBC NISP	Financials	Indonesia	5,380	1.2%
Syngene International	Health Care	India	5,272	1.2%
Hualan Biological Engineering	Health Care	China	5,241	1.2%
Tokyo Electron	Information Technology	Japan	5,061	1.2%
PT Selamat Sempurna	Consumer Discretionary	Indonesia	4,871	1.1%
Top 40 Investments			354,406	81.5%
Marico Bangladesh	Consumer Staples	Bangladesh	4,744	1.1%
Shenzhen Inovance Technology	Industrials	China	4,707	1.1%
Mahindra Logistics	Industrials	India	4,453	1.0%
HDFC Life Insurance	Financials	India	4,133	1.0%
BRAC Bank	Financials	Bangladesh	4,107	0.9%
Shanthi Gears	Industrials	India	4,087	0.9%
Centre Testing International	Industrials	China	4,079	0.9%
Guangzhou Kingmed Diagnostics	Health Care	China	3,684	0.8%
Humanica	Information Technology	Thailand	3,644	0.8%
Glodon	Information Technology	China	3,031	0.7%
Top 50 Investments			395,075	90.7%
Estun Automation	Industrials	China	2,848	0.7%
Delta Brac Housing Finance	Financials	Bangladesh	2,677	0.6%
Cholamandalam Financial Holdings	Financials	India	2,427	0.6%
Pigeon Corporation	Consumer Staples	Japan	2,401	0.6%
MediaTek	Information Technology	Taiwan	2,223	0.5%
Kasikornbank	Financials	Thailand	2,180	0.5%
Amoy Diagnostics	Health Care	China	2,148	0.5%
Biocon	Health Care	India	2,081	0.5%
Hemas Holdings	Industrials	Sri Lanka	2,001	0.5%
IndiaMart InterMesh	Information Technology	India	1,781	0.4%
AK Medical Holdings	Health Care	China	1,494	0.3%
Pentamaster International	Information Technology	Malaysia	1,371	0.3%
Cyient	Information Technology	India	831	0.2%
Nippon Paint	Materials	Japan	809	0.2%
Square Pharmaceuticals	Health Care	Bangladesh	156	0.0%
Total Investments			422,503	97.1%
Net current assets / (liabilities)			12,470	2.9%
Total Shareholders Funds			434,973	100.0%

Financial Statements

Income Statement

for the six months ended 31 July 2021

	(Unaudited) Six months ended 31 July 2021			(Unaudited) Six months ended 31 July 2020
	Revenue £000	Capital £000	Total £000	Revenue £000	Capital £000	Total £000
Gains on investments	–	24,349	24,349	–	1,966	1,966
Exchange differences on currency balances	–	(463)	(463)	–	(87)	(87)
Investment Income	3,094	–	3,094	3,035	–	3,035
Portfolio Management and AIFM fees (note 2)	(514)	(1,542)	(2,056)	(389)	(1,166)	(1,555)
Other expenses	(344)	–	(344)	(288)	–	(288)
Return before taxation	2,236	22,344	24,580	2,358	713	3,071
Taxation	(415)	(2,505)	(2,920)	(301)	1,117	816
Return after taxation	1,821	19,839	21,660	2,057	1,830	3,887
Return per ordinary share (note 3)	1.5p	16.4p	17.9p	1.7p	1.5p	3.2p

The Total column of this statement represents the Company’s Income Statement.

The Revenue and Capital columns are supplementary to this and are both prepared under guidance published by the Association of Investment Companies (“AIC”).

All revenue and capital items in the Income Statement derive from continuing operations.

The Company had no recognised gains or losses other than those declared in the Income Statement.

All of the return and total comprehensive income for the period is attributable to the owners of the Company.

Statement of Changes in Equity

for the six months ended 31 July 2021

	(Unaudited)	(Unaudited)
	Six months	Six months
	ended	ended
	31 July 2021	31 July 2020
	£000	£000
Opening shareholders’ funds	416,216	345,717
Return for the period	21,660	3,887
Dividends paid (note 4)	(2,903)	(3,629)
Closing shareholders’ funds	434,973	345,975

Statement of Financial Position

as at 31 July 2021

	(Unaudited)	(Audited)
	As at	As at
	31 July	31 January
	2021	2021
	£000	£000
Fixed assets
Investments (note 5)	422,503	404,714
Current assets
Debtors	3,407	232
Cash and cash equivalents	19,501	17,823
	22,908	18,055
Creditors (amounts falling due within one year)	(2,718)	(1,231)
Net current assets	20,190	16,824
Non-current liabilities
Provisions (note 6)	(7,720)	(5,322)
Net assets	434,973	416,216
Capital and reserves
Share capital	15,120	15,120
Share premium account	8,811	8,811
Capital redemption reserve	1,648	1,648
Special reserve	14,572	14,572
Capital reserve	389,114	369,275
Revenue reserve	5,708	6,790
Equity shareholders’ funds	434,973	416,216
Net asset value per ordinary share (note 7)	359.6p	344.1p

Notes to the Financial Statements

1. Basis of preparation

The condensed Financial Statements for the six months to 31 July 2021 comprise the statements set out above including the related notes below. They have been prepared in accordance with FRS 104 ‘Interim Financial Reporting’ and the principles of the AIC’s Statement of Recommended Practice issued in October 2019 and updated in April 2021, using the same accounting policies as set out in the Company’s Annual Report and Financial Statements for the year ended 31 January 2021.

Fair value

Under FRS 102 and FRS 104 investments have been classified using the following fair value hierarchy:

Level 1 – Quoted prices in active markets.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data), either directly or indirectly.

Level 3 – Inputs are unobservable (i.e. for which market data is unavailable).

All of the Company’s investments fall into Level 1 for the periods reported.

2. Portfolio Management and AIFM fees*

	(Unaudited) Six months ended 31 July 2021			(Unaudited) Six months ended 31 July 2020
	Revenue	Capital	Total	Revenue	Capital	Total
	£000	£000	£000	£000	£000	£000
Portfolio management fee – Stewart Investors	456	1,369	1,825	344	1,032	1,376
AIFM fee – Frostrow	58	173	231	45	134	179
	514	1,542	2,056	389	1,166	1,555

* Please refer to the most recent annual report for more details of the management fee structure.

3. Return per ordinary share

The total return per ordinary share is based on the return attributable to shareholders of £21,660,000 (six months ended 31 July 2020: return of £3,887,000) and on 120,958,386 shares (six months ended 31 July 2020: 120,958,386 shares), being the weighted average number of shares in issue.

The revenue return per ordinary share is calculated by dividing the revenue return attributable to shareholders of £1,821,000 (six months ended 31 July 2020: £2,057,000) by the weighted average number of shares in issue as above.

The capital return per ordinary share is calculated by dividing the capital return attributable to shareholders of £19,839,000 (six months ended 31 July 2020: return of £1,830,000) by the weighted average number of shares in issue as above.

4. Dividends

	(Unaudited)	(Unaudited)
	Six months	Six months
	ended	ended
	31 July 2021	31 July 2020
Amounts recognised as distributions in the period:
Previous year’s final dividend of 2.4p (2020: interim dividend of 3.0p)	2,903	3,629

5. Investments

	Six months to		Year to
	31 July	31 July	31 January
	2021	2020	2021
Investments
Cost at start of period	267,140	222,736	222,736
Investment holding gains at start of period	137,574	86,781	86,781
Valuation at start of period	404,714	309,517	309,517
Purchases at cost	37,762	63,520	110,858
Disposal proceeds	(44,322)	(41,245)	(92,887)
Gains on investments	24,349	1,966	77,226
Valuation at end of period	422,503	333,758	404,714
Cost at end of period	275,584	252,451	267,140
Investment holding gains at end of period	146,919	81,307	137,574
Valuation at end of period	422,503	333,758	404,714

The Company received £44,322,000 (period to 31 July 2020: £41,245,000; year to 31 January 2021: £92,887,000) from investments sold in the period. The book cost of these investments when they were purchased was £29,318,000 (period to 31 July 2020: £33,805,000; year to 31 January 2021: £66,454,000). These investments have been revalued over time and until they were sold any unrealised gains/losses were included in the fair value of the investments.

During the period the Company incurred transaction costs on purchases of £63,000 (period to 31 July 2020: £76,000; year to 31 January 2021: £156,000) and transaction costs on sales of £116,000 (period to 31 July 2020: £89,000; year to 31 January 2021: £231,000).

6. Provisions

The provision at 31 July 2021 of £7,720,000 (31 January 2021: £5,322,000) relates to a potential deferred tax liability for Indian capital gains tax that may arise on the Company’s Indian investments should they be sold in the future, based on the net unrealised taxable capital gain at the period end and on enacted Indian tax rates. The amount of any future tax amounts payable may differ from this provision, depending on the value and timing of any future sales of such investments and future Indian tax rates.

The capital tax charge shown in the Income Statement primarily results from the movements on this provision.

7. Net asset value per ordinary share

The net asset value per ordinary share is based on the net assets attributable to shareholders of £434,973,000 (31 January 2021: £416,216,000) and on 120,958,386 shares in issue (31 January 2021: 120,958,386).

8. 2021 accounts

These are not statutory accounts in terms of Section 434 of the Companies Act 2006 and are unaudited. Statutory accounts for the year to 31 January 2021, which received an unqualified audit report, have been lodged with the Registrar of Companies. No statutory accounts in respect of any period after 31 January 2021 have been reported on by an auditor or delivered to the Registrar of Companies.

Earnings for the first six months should not be taken as a guide to the results for the full year.

Interim Management Report

Principal Risks and Uncertainties

The Company’s principal area of risk relates to its investment activity and strategy, including currency risk in respect of the markets in which it invests. Other risks faced by the Company include financial, shareholder relations and operational risks (including cyber-crime, corporate governance, accounting, legal, regulatory and political risks). These risks, and the way in which they are managed, are described in more detail under the heading Risk Management within the Strategic Report in the Company’s Annual Report for the year ended 31 January 2021. The Company’s principal risks and uncertainties have not changed materially since the date of that report and are not expected to change materially for the remaining six months of the Company’s financial year.

The Board, the AIFM and the Portfolio Manager continually consider emerging risks and monitor, amongst other things, the potential for the Company’s portfolio to be a?ected by the Covid-19 pandemic and geopolitical risks.

Related Party Transactions

During the first six months of the current financial year no material transactions with related parties have taken place which have affected the financial position or the performance of the Company during the period.

Going Concern

The Directors believe, having considered the Company’s investment objective, risk management policies, capital management policies and procedures, and the nature of the portfolio and its expenditure projections, that the Company has adequate resources, an appropriate financial structure and suitable management arrangements in place to continue in operational existence for the foreseeable future. For these reasons, they consider it appropriate to continue to adopt the going concern basis in preparing the financial statements. In reviewing the position as at the date of this report, the Board has considered the guidance on this matter issued by the Financial Reporting Council.

Directors’ Responsibilities

The Board confirms that, to the best of the Directors’ knowledge:

1. the condensed set of financial statements contained within the Half Year Report has been prepared in accordance with Financial Reporting Standard 104 (Interim Financial Reporting); and
2. the interim management report includes a fair review of the information required by:
   1. DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
   2. DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.

This Half Year Report has not been audited or reviewed by an auditor.

This Half Year Report contains certain forward-looking statements. These statements are made by the Directors in good faith based on the information available to them up to the date of this report and such statements should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying any such forward-looking information.

For and on behalf of the Board

James Williams

Chairman

25 October 2021

Frostrow Capital LLP

Company Secretary

Glossary of Terms

AIFMD

The Alternative Investment Fund Managers Directive (the “Directive”) is a European Union Directive that entered into force on 22 July 2013. The Directive, which was retained in UK law following the withdrawal of the UK from the European Union, regulates fund managers that manage alternative investment funds (including investment trusts).

Where an entity falls within the scope of the Directive, it must appoint a single Alternative Investment Fund Manager (“AIFM”). The core functions of an AIFM are portfolio and risk management. An AIFM can delegate one but not both of these functions. The entity must also appoint an independent depositary whose duties include the following: the safeguarding and verification of ownership of assets; the monitoring of cashflows; and ensuring that appropriate valuations are applied to the entity’s assets

Alternative Performance Measures (“APMs”)

Measures that are not specifically defined under International Financial Reporting Standards, but which the Board of Directors views as particularly relevant for investment trust companies and which it uses to assess the Company’s performance. Definitions of the terms used and the basis of calculation are set out in this Glossary and the APMs are indicated with a caret (^).

Average Discount

The average share price for the period divided by the average net asset value for the period and expressed as a percentage (%).

	Six months to	Year to
	31 July	31 January
	2021	2021
	pence	pence
Average share price for the period	330.0	268.1
Average net asset value for the period	354.9	294.9
Average Discount	7.0%	9.1%

Net Asset Value Per Share

The value of the Company’s assets, principally investments made in other companies and cash held in the Company's bank accounts, minus any liabilities and divided by the number of shares in issue. The net asset value is often expressed in pence per share and it may also be described as ‘shareholders’ funds’ per share. The net asset value per share is unlikely to be the same as the share price, which is the price at which the Company’s shares can be bought or sold by an investor. The share price is determined by the relationship between the demand for and supply of the shares.

Net Asset Value Per Share Total Return^

The theoretical total return on shareholders’ funds per share, reflecting the change in net asset value assuming that dividends paid to shareholders were reinvested at net asset value at the time the shares were quoted ex-dividend. A way of measuring investment management performance of investment trusts which is not affected by movements in the share price.

	Six months to	Year to
	31 July	31 January
	2021	2021
NAV Total Return	pence	pence
Opening net asset value per share	344.1	285.8
Increase in net asset value	17.9	61.3
Dividend paid	(2.4)	(3.0)
Closing Net Asset Value	359.6	344.1
% increase in net asset value	5.2%	21.4%
Impact of reinvested dividends	0.4%	0.9%
Net Asset Value Per Share Total Return	5.6%	22.3%

Ongoing Charges^{^}

Ongoing charges are calculated by taking the Company’s annualised operating expenses excluding finance costs, taxation and exceptional items, and expressing them as a percentage of the average daily net asset value of the Company over the period. The costs of buying and selling investments are excluded, as are interest costs, taxation, costs of buying back or issuing shares and other non-recurring costs. These items are excluded because if included, they could distort the understanding of the Company’s performance for the period and the comparability between periods.

	Six months to	Year to
	31 July	31 January
	2021	2021
	£000	£000
Total Operating Expenses	2,400	4,010
Average Net Assets	429,540	356,104
Ongoing Charges*	1.1%	1.1%

* Annualised

Performance Objective

The Company’s performance objective is to provide shareholders with a net asset value per share total return in excess of the UK Consumer Price Index (“CPI”) plus 6 per cent. (calculated on an annual basis) measured over three to five years. The Consumer Price Index is published by the UK Office for National Statistics and represents inflation. The additional 6% is a fixed element to represent what the Board considers to be a reasonable premium on investors’ capital which investing in the faster-growing Asian economies ought to provide over time.

	Company Net
	Asset Value
	Per Share
	Total Return	CPI + 6%
	(annualised)	(annualised)
	(%)	(%)
One year to 31 July 2021	26.6	8.3
Three years to 31 July 2021	9.5	8.0
Five years to 31 July 2021	10.7	8.3

Share Price Discount (or Premium) to the Net Asset Value Per Share^{^}

A description of the difference between the share price and the net asset value per share. The size of the discount or premium is calculated by subtracting the share price from the net asset value per share and is usually expressed as a percentage (%) of the net asset value per share. If the share price is higher than the net asset value per share the result is a premium. If the share price is lower than the net asset value per share, the shares are trading at a discount.

Share Price Total Return^{^}

Share price total return to a shareholder, on a last traded price to a last traded price basis, assuming that all dividends received were reinvested, without transaction costs, into the shares of the Company at the time the shares were quoted ex-dividend.

	Six months to	Year to
	31 July	31 January
	2021	2021
Share Price Total Return	pence	pence
Opening share price	333.0	268.0
Increase in share price	5.4	68.0
Dividend Paid	(2.4)	(3.0)
Closing share price	336.0	333.0
% increase in share price	1.6%	25.4%
Impact of reinvested dividends	0.1%	0.4%
Share Price Total Return	1.7%	25.8%

MSCI Disclaimer

The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its a?liates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation lost profits) or any other damages. (www.msci.com)

A member of the Association of Investment Companies

Pacific Assets Trust plc

Address for correspondence – 25 Southampton Buildings, London WC2A 1AL

www.pacific-assets.co.uk